Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone321-534-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$176.13 million
Profitability
Miscellaneous
Employees600
OptionableOptionable
GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions
What is GALAPAGOS NV/S's stock symbol?
GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."
When is GALAPAGOS NV/S's next earnings date?
What price target have analysts set for GLPG?
11 analysts have issued 1-year target prices for GALAPAGOS NV/S's stock. Their predictions range from $90.00 to $157.00. On average, they expect GALAPAGOS NV/S's share price to reach $123.4444 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S.
What is the consensus analysts' recommendation for GALAPAGOS NV/S?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S.
Has GALAPAGOS NV/S been receiving favorable news coverage?
Media coverage about GLPG stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of GALAPAGOS NV/S's key competitors?
Some companies that are related to GALAPAGOS NV/S include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE).
Who are GALAPAGOS NV/S's key executives?
GALAPAGOS NV/S's management team includes the folowing people:
- Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
- Mr. Bart Filius MBA, CFO & COO (Age 49)
- Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
- Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
- Dr. Andre Hoekema, Chief Bus. Officer (Age 62)
When did GALAPAGOS NV/S IPO?
(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.
Who are GALAPAGOS NV/S's major shareholders?
GALAPAGOS NV/S's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.62%), Bank of New York Mellon Corp (0.49%), Peregrine Capital Management LLC (0.17%), Alps Advisors Inc. (0.15%), Millennium Management LLC (0.14%) and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp (0.12%).
Which major investors are selling GALAPAGOS NV/S stock?
GLPG stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, BlackRock Inc., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Dorsey Wright & Associates, Alps Advisors Inc., Castleark Management LLC, Stifel Financial Corp and Bank of Montreal Can.
Which major investors are buying GALAPAGOS NV/S stock?
GLPG stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Prosight Management LP, OLD Mission Capital LLC, D. E. Shaw & Co. Inc., Victory Capital Management Inc., Millennium Management LLC, FNY Investment Advisers LLC and Townsquare Capital LLC.
How do I buy shares of GALAPAGOS NV/S?
Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GALAPAGOS NV/S's stock price today?
One share of GLPG stock can currently be purchased for approximately $101.70.
How big of a company is GALAPAGOS NV/S?
GALAPAGOS NV/S has a market capitalization of $5.21 billion and generates $176.13 million in revenue each year. The biotechnology company earns $-130,780,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. GALAPAGOS NV/S employs 600 workers across the globe.
What is GALAPAGOS NV/S's official website?
How can I contact GALAPAGOS NV/S?
GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]
MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
